Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Geriatr Psychiatry Neurol ; 35(6): 840-845, 2022 11.
Article in English | MEDLINE | ID: mdl-35383492

ABSTRACT

Anticholinergic medications, such as oxybutynin, are first-line pharmacologic therapies in overactive bladder. However, the cognitive adverse effect profiles of frequently used anticholinergic medications are extensive and limit their use in older patients. Additionally, many older patients continue on anticholinergic therapy if adverse effects are not self-reported by the patient or detected by the provider.Here, we present a case of a 73-year-old male with a history of major neurocognitive disorder, in which unreported oxybutynin overuse led to repeated delirious states, erratic driving, and subsequent psychiatric hospitalizations. During his hospitalizations, he displayed progressively more linear thought processes and improved insight without clear etiology. After a more thorough history of his medication use was obtained, he disclosed that he would often take additional doses of oxybutynin to prevent incontinence during car rides and had done so prior to recent hospitalizations.Our example highlights the importance of thorough history taking, medication review, reducing polypharmacy, careful patient education about medications with psychiatric adverse effects, and, importantly, the avoidance of anticholinergic medication prescription in older patients.


Subject(s)
Delirium , Urinary Bladder, Overactive , Male , Humans , Aged , Mandelic Acids/adverse effects , Urinary Bladder, Overactive/chemically induced , Urinary Bladder, Overactive/drug therapy , Cholinergic Antagonists/adverse effects , Delirium/chemically induced
SELECTION OF CITATIONS
SEARCH DETAIL
...